Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

779.67 -2.71 (-0.35%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

49 50 Next >

The One-Minute Market Report - Sunday, Oct. 2 ↗

October 02, 2022

In today's issue of the One-Minute Market Report, I examine the damage done in September and highlight the parts of the market that were hit the hardest.

Via Talk Markets

10 Health Care Stocks Whale Activity In Today's Session ↗

September 29, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis ↗

September 29, 2022

Via Benzinga

Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea ↗

September 27, 2022

Via Benzinga

The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market ↗

September 27, 2022

Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market.

Via InvestorPlace

Regeneron's Bispecific Antibodies Show Encouraging Anti Tumor Activity ↗

September 12, 2022

Via Benzinga

Analyst Ratings for Regeneron Pharmaceuticals ↗

September 09, 2022

Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:

Via Benzinga

Can Healthcare Stocks Continue To Outperform? ↗

September 26, 2022

Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis.

Via Talk Markets

The Top 5 Stocks Cathie Wood Is Buying This Week ↗

September 23, 2022

Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys.

Via InvestorPlace

Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test ↗

September 23, 2022

Though successful in early testing, it wasn't enough to win a Phase 3 study.

Via Investor's Business Daily

$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today ↗

September 20, 2022

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.71% on an annualized basis producing an average annual return of 16.96%. Currently, Regeneron...

Via Benzinga

Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders ↗

September 19, 2022

Via Benzinga

WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete ↗

September 16, 2022

Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies.

Via Benzinga

Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies ↗

September 16, 2022

Via Benzinga

Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗

September 16, 2022

Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.

Via Investor's Business Daily

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗

September 15, 2022

Via Benzinga

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers ↗

September 15, 2022

Via Benzinga

US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing ↗

September 14, 2022

Via Benzinga

ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients ↗

September 14, 2022

Via Benzinga

Biden Administration Pushes 'Cancer Moonshot' Initiative: Report ↗

September 13, 2022

President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it." The...

Via Benzinga

A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says ↗

September 13, 2022

Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati

Via Benzinga

9 Analysts Have This to Say About Regeneron Pharmaceuticals ↗

September 09, 2022

Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:

Via Benzinga

Jefferies Upgrades Regeneron Pharmaceuticals: Here's What You Need To Know ↗

September 09, 2022

Jefferies upgraded its rating of Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold with a price target of $675.00, changing its price target from $536.00 to $675.00. Shares of Regeneron Pharmaceuticals...

Via Benzinga

'Highly Compelling' Eye Drug Data Has Wall Street Stampeding To Buy This 'Large Cap Growth Story.' Even After $15B In Market Cap Was Added ↗

September 09, 2022

Via Benzinga

What 9 Analyst Ratings Have To Say About Regeneron Pharmaceuticals ↗

September 09, 2022

Over the past 3 months, 9 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday ↗

September 09, 2022

Morgan Stanley raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from $625 to $851. Morgan Stanley analyst Matthew Harrison also upgraded the stock from Equal-Weight to...

Via Benzinga

US Stock Futures Surge; Fed Speakers In Focus ↗

September 09, 2022

Pre-open movers U.S. stock futures traded higher in early pre-market trade after recording gains on Thursday. The Dow Jones jumped around 193 points, while the Nasdaq Composite climbed 0.6% in the...

Via Benzinga

Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday ↗

September 09, 2022

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to...

Via Benzinga

< Previous 1 2

...

30 31 32 33 34 35 36 37 38

...

49 50 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Regeneron Pharmaceuticals (NQ:REGN)

Headline News about Regeneron Pharmaceuticals

Starting at $3.75/week.

Subscribe Today